TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Grifols SA ( (GRFS) ) has issued an update.
On November 4, 2025, Grifols reported its third-quarter financial results, highlighting a 9.1% year-over-year revenue increase to EUR 1,865 million, driven by the Biopharma business. The company achieved a group profit of EUR 127 million for the quarter, contributing to a 245% year-to-date profit increase. Grifols also improved its leverage ratio to 4.2x and maintained robust liquidity of EUR 1,475 million. The company continues to focus on free cash flow generation and strategic market positioning, with its immunoglobulin franchise showing significant growth.
The most recent analyst rating on (GRFS) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Grifols SA stock, see the GRFS Stock Forecast page.
Spark’s Take on GRFS Stock
According to Spark, TipRanks’ AI Analyst, GRFS is a Neutral.
Grifols SA’s overall stock score is driven by strong earnings call results and improving financial performance, despite high leverage and moderate valuation metrics. Technical indicators suggest a neutral to bearish trend, which slightly offsets the positive earnings outlook.
To see Spark’s full report on GRFS stock, click here.
More about Grifols SA
Grifols, S.A. is a global healthcare company based in Barcelona, Spain, specializing in the production of plasma-derived medicines. The company operates primarily in the biopharmaceutical sector, focusing on products such as immunoglobulins, albumin, and specialty proteins, with a strong market presence in the treatment of immunodeficiencies and other conditions.
Average Trading Volume: 658,121
Technical Sentiment Signal: Hold
Current Market Cap: $7.86B
For a thorough assessment of GRFS stock, go to TipRanks’ Stock Analysis page.